Immunocore (IMCR) to Release Quarterly Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Immunocore to post earnings of ($0.26) per share and revenue of $143.5420 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 2:00 AM ET.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.60) EPS for the quarter. The business had revenue of $104.48 million during the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%. On average, analysts expect Immunocore to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Immunocore Stock Performance

NASDAQ:IMCR opened at $28.16 on Monday. The company has a fifty day simple moving average of $31.05 and a two-hundred day simple moving average of $33.40. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -40.23 and a beta of 0.74. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. Immunocore has a 52 week low of $27.44 and a 52 week high of $40.71.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. UBS Group set a $55.00 price target on shares of Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Zacks Research downgraded shares of Immunocore from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Monday, April 20th. Finally, Needham & Company LLC boosted their target price on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $60.89.

Insider Activity

In other Immunocore news, insider David M. Berman sold 5,965 shares of Immunocore stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $192,967.75. Following the transaction, the insider owned 5,859 shares in the company, valued at $189,538.65. This trade represents a 50.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bahija Jallal sold 11,474 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at approximately $399,296.05. This represents a 48.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 19,137 shares of company stock worth $619,082 over the last ninety days. 10.40% of the stock is currently owned by insiders.

Institutional Trading of Immunocore

A number of hedge funds and other institutional investors have recently made changes to their positions in IMCR. Arax Advisory Partners raised its holdings in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after purchasing an additional 1,042 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares during the period. State of Tennessee Department of Treasury bought a new stake in shares of Immunocore during the 2nd quarter worth $132,000. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Immunocore by 162.1% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock worth $190,000 after buying an additional 3,388 shares during the period. Finally, Cetera Investment Advisers bought a new stake in shares of Immunocore during the 4th quarter worth $203,000. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.